1 An interview with Geoffrey Guy, GW Pharmaceuticals, on new UK Early Access to Medicine Scheme
event strap

An interview with Geoffrey Guy, GW Pharmaceuticals, on new UK Early Access to Medicine Scheme

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Explore whether or not the UK's Early Access to Medicines Scheme is a positive step forward

In March 2014 the UK Early Access to Medicines Scheme was launched, and within two weeks an Adaptive Licencing initiative was also launched by the European Medicines Agency (EMA). These two programmes present new opportunities to enable earlier drug access to the market, giving patients with rare diseases quicker access to potentially life saving drugs.

In this report we speak with Geoffrey Guy, Founder and Chairman of GW Pharmaceuticals, about the UK Early Access to Medicines Scheme and whether or not it is a positive step forward.

Download the report now to learn more about Geoffrey's thoughts on:

  • Whether the global market for fast tracking orphan drugs is healthy or not
  • If the new UK Early Access to Medicines Scheme is doing enough to facilitate early access
  • The main challenge that the scheme will face in the next year
  • The top five things that the UK can learn from the US early access schemes